VivoSeq
Infectious Disease

Septic Shock

163

Pipeline Programs↗

43

Active Trials↗

52

Companies Involved↗

Septic Shock is a highly competitive landscape with 163 programs across 52 companies. The most active players are Bristol-Myers Squibb, Merck & Co., Ferring. 33 therapies are approved with 41 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

48/100

Mech. Concentration

11/100

Completion Rate

78/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Merck & Co. logo

Merck & Co.

3 programs

Phase 2Ferring logo

Ferring

1 program

Phase 2L

Leading BioSciences, Inc

1 program

Phase 2Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

1 program

Phase 2W

WestVac Biopharma Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical44

Daptomycin

Baxter Healthcare Corporation

Doripenem

Shionogi

Imipenem

Pfizer

Metformin

EMD Serono

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 13

Nivolumab

Bristol-Myers Squibb

Allogeneic Mesenchymal Stromal Cells

Ottawa Hospital Research Institute

Sodium Ascorbate

Jeanne Drisko, MD, CNS, FACN

Phase 242

Levosimendan

Orion Corporation, Orion Pharma

Esmolol

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Dobutamine

Eli Lilly

Heparin

Baxter Healthcare Corporation

Nangibotide

Inotrem

Phase 341

Thiamine

Universiti Kebangsaan Malaysia Medical Centre

Iloprost

BTG International Inc.

Norepinephrine

General Hospital of Ningxia Medical University

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ivabradine

Amgen

Approved33

Tranexamic Acid

Amring

Propofol

Fresenius Kabi Oncology Ltd.

Fentanyl

Cephalon

Eptifibatide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Midodrine

Takeda

Analysis

Modality Breakdown

95%

Small molecule

192 of 202 classified programs — the dominant modality here.

5%ALL OTHERSPeptide42%Monoclonal antibody31%Cell therapy31%

Small molecule leads; the ring shows all 202 classified programs, each share of the total. Modality classified for 98% of 225 pipeline programs.

Analysis

Trial Status

282

clinical trials

Completed139 · 49%
Unknown status60 · 21%
Terminated26 · 9%
Recruiting23 · 8%
Not yet recruiting16 · 6%
Withdrawn12 · 4%
Other6 · 2%

Clinical Trials

Trial Activity

282 trials

Albumin and Crystalloid Administration in Septic Shock
Recruiting·—·Phase 4·NCT05148286·2,426 enrolled
Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study
Recruiting·UUniversity Hospital, Angers·N/A·NCT04288635·55 enrolled
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy
Recruiting·AArtcline GmbH·Phase 2·NCT05442710·142 enrolled
Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial
Recruiting·—·Phase 4·NCT06670963·200 enrolled
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock
Recruiting·OOttawa Hospital Research Institute·Phase 2·NCT05969275·296 enrolled
Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication
Recruiting·—·N/A·NCT07255378·1,200 enrolled
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
Recruiting·VVivacelle Bio·Phase 3·NCT06072430·46 enrolled
Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock
Recruiting·NNorthern Jiangsu People's Hospital·Phase 4·NCT07383103·336 enrolled
Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock
Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT06481410·488 enrolled
Stress Hydrocortisone In Pediatric Septic Shock
Recruiting·—·Phase 3·NCT03401398·500 enrolled
Early Versus Late Adjunctive Vasopressin in Septic Shock
Recruiting·TThe Cleveland Clinic·Phase 4·NCT06709573·300 enrolled
Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility
Recruiting·—·Phase 3·NCT04748796·360 enrolled
Early Methylene Blue in the Microhemodynamics of Septic Shock Patients
Recruiting·CCentro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva·Phase 2/3·NCT07264543·50 enrolled
Early Versus Conventional Cessation of Hydrocortisone in Septic Shock
Recruiting·MMahidol University·Phase 2·NCT05818826·160 enrolled
Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
Recruiting·—·N/A·NCT07203833·144 enrolled
Page 1 of 19

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)